Cetirizine hydrochloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1995
- First approval year
- 1995
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Cetirizine hydrochloride
- Molecular weight
- 461.82
- Structure (SMILES)
- Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
- allacan
- Allacan
- allertek
- Allertek
- becoallergy
- Becoallergy
- cetec
- Cetec
- cetirizine hydrochloride
- Cetirizine hydrochloride
- cetirizine hydrochloride allergy
- Cetirizine hydrochloride allergy
- cetirizine hydrochloride component of zyrtec d
- Cetirizine hydrochloride component of zyrtec-d
- cetirizine hydrochloride hives
- Cetirizine hydrochloride hives
- cetirizine hydrochloride hives relief
- Cetirizine hydrochloride hives relief
- cetirocol
- Cetirocol
- children s cetirizine hydrochloride allergy
- children s cetirizine hydrochloride hives relief
- children s zyrtec allergy
- children s zyrtec hives relief
- Children's cetirizine hydrochloride allergy
And 23 more, listed on the interactive page.
- acetic acid 2 4 4 chlorophenyl phenylmethyl 1 piperazinyl ethoxy dihydrochloride
- Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride, (±)-
- cetirizine dihydrochloride
- Cetirizine dihydrochloride
- cetirizine dihydrochloride (rescue medication)
- Cetirizine dihydrochloride [EP MONOGRAPH]
- Cetirizine dihydrochloride [MI]
- cetirizine dihydrochloride ep monograph
- cetirizine dihydrochloride mi
- cetirizine dihydrochloride rescue medication
- cetirizine hcl
- Cetirizine hcl
- cetirizine hydrochloride
- Cetirizine hydrochloride
- Cetirizine hydrochloride [JAN]
- Cetirizine hydrochloride [MART.]
- Cetirizine hydrochloride [ORANGE BOOK]
- Cetirizine hydrochloride [USAN]
- Cetirizine hydrochloride [USP MONOGRAPH]
- Cetirizine hydrochloride [USP-RS]
- Cetirizine hydrochloride [VANDF]
- Cetirizine hydrochloride [WHO-DD]
- cetirizine hydrochloride jan
- cetirizine hydrochloride mart
- cetirizine hydrochloride orange book
And 19 more, listed on the interactive page.
- CAS registry numbers
- 83881-52-1
- ChEMBL ID
- CHEMBL1607273
- InChIKey
- PGLIUCLTXOYQMV-UHFFFAOYSA-N
- RxNorm IDs (RxCUI)
- 203150
- FDA ingredient codes (UNII)
- 64O047KTOA
- 55182
- 44659863
- 57515953
- Applicant
- KENVUE BRANDS
- Approval date
- 8 Dec 1995
- Application number
- NDA019835
- Patents
- 11
- Designations
- 0
- Earliest recorded loss of exclusivity
- 9 Jan 2033
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
Administration routes
- Oral
- Parenteral
- topical
Mechanisms of action
- Mechanism
- Histamine H1 receptor antagonist
- Action type
- Antagonist
- Target
- Histamine H1 receptor
- Protein identifier
- P35367
Open Targets mechanisms
- Mechanism
- Histamine H1 receptor antagonist
- Action type
- Antagonist
- Target
- Histamine H1 receptor
- Condition
- Prostatitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003830
- Subject identifier
- D011472
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003956
- Subject identifier
- D006255
- Condition
- Urticaria
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005531
- Subject identifier
- D014581
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005854
- Subject identifier
- D006255
- Condition
- Conjunctivitis, Allergic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007141
- Subject identifier
- D003233
- Condition
- Rhinitis, Allergic, Perennial
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001417
- Subject identifier
- D012221
- Condition
- Pruritus
- Highest recorded phase
- 4
- Condition identifier
- HP:0000989
- Subject identifier
- D011537
- Condition
- Nasal Obstruction
- Highest recorded phase
- 4
- Condition identifier
- HP:0001742
- Subject identifier
- D015508
- Condition
- Hypersensitivity
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005271
- Subject identifier
- D006967
- Condition identifier
- EFO_0003830
- Condition identifier
- EFO_0003956
- Condition identifier
- EFO_0005531
- Condition identifier
- EFO_0005854
- Condition identifier
- EFO_0007141
- Condition identifier
- EFO_1001417
- Condition identifier
- HP_0000989
- Condition identifier
- HP_0000989
- Highest recorded phase
- 4
- Condition identifier
- HP_0001742
- Condition identifier
- HP_0001742
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005271
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005324
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005492
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005642
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0011786
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0022103
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0024332
- Highest recorded phase
- 4
- Event
- abdominal discomfort
- Reports
- 2,158
- Reporting signal score
- 6,206.32
- Event
- alopecia
- Reports
- 2,131
- Reporting signal score
- 6,067.63
- Event
- angioedema
- Reports
- 208
- Reporting signal score
- 196.208
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 938
- Reporting signal score
- 4,708.58
- Event
- arthralgia
- Reports
- 690
- Reporting signal score
- 497.334
- Event
- arthropathy
- Reports
- 1,382
- Reporting signal score
- 4,276.19
- Event
- asthma
- Reports
- 213
- Reporting signal score
- 198.03
- Event
- blister
- Reports
- 484
- Reporting signal score
- 1,039.27
- Event
- blood cholesterol increased
- Reports
- 225
- Reporting signal score
- 381.063
- Event
- bursitis
- Reports
- 97
- Reporting signal score
- 199.541
- Event
- chronic spontaneous urticaria
- Reports
- 34
- Reporting signal score
- 117.471
- Event
- coeliac disease
- Reports
- 88
- Reporting signal score
- 217.422
- Event
- condition aggravated
- Reports
- 879
- Reporting signal score
- 975.665
- Event
- confusional state
- Reports
- 399
- Reporting signal score
- 345.294
- Event
- contusion
- Reports
- 274
- Reporting signal score
- 325.112
- Event
- discomfort
- Reports
- 1,212
- Reporting signal score
- 4,044.13
- Event
- drug hypersensitivity
- Reports
- 399
- Reporting signal score
- 173.572
- Event
- drug intolerance
- Reports
- 1,257
- Reporting signal score
- 2,809.77
- Event
- drug tolerance decreased
- Reports
- 45
- Reporting signal score
- 125.51
- Event
- dry mouth
- Reports
- 128
- Reporting signal score
- 101.056
- Event
- duodenal ulcer perforation
- Reports
- 605
- Reporting signal score
- 2,879.39
- Event
- dyspnoea
- Reports
- 559
- Reporting signal score
- 151.814
- Event
- electric shock
- Reports
- 34
- Reporting signal score
- 124.415
- Event
- erythema
- Reports
- 233
- Reporting signal score
- 106.817
- Event
- fatigue
- Reports
- 2,052
- Reporting signal score
- 2,409.29
And 59 more, listed on the interactive page.
- NCT00533637
- NCT00881127
- NCT00881634
- NCT04071821
- NCT01651871
- NCT02024152
- NCT03167216
- Dose
- 10 mg
- How often
- Once daily
Conditions of use
- Do not take more than one 10 mg tablet in 24 hours
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 53.01
- Calculated partition coefficient (ALogP)
- 3.15
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 29
- Molecular formula
- C21H27Cl3N2O3
- Monoisotopic mass
- 460.108726
- Natural product
- No
- 0121-0874
- 16571-134
- 23155-929
- 45802-626
- 61037-479
- 62135-057
- 65162-684
- 68118-200
- 69206-990
- 69452-426
- 70720-100
- 71205-435
- 72888-480
- 83745-185
- 50090-5220
- 51672-4070
- 68788-8282
- 68788-8523
- 68788-8890
- Recorded assays
- 957
- Active assays
- 8
- Confirmatory
- Other
- Screening
- Summary
- Anti-Allergic Agents
- Histamine H1 Antagonists, Non-Sedating
Related records
Trials (124)
- 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)
- A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)
- A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)
- A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis
- A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine
- A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
- A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
- A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
- A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
- A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Approved for (5)
- Allergic rhinitis
- Atopic conjunctivitis
- Perennial allergic rhinitis
- Seasonal allergic rhinitis
- Urticaria
In development for (2)
- Allergic disease Phase 1
- Prostatitis Early phase 1
Targets (1)
- HRH1 Histamine H1 receptor antagonist